Status:
COMPLETED
Aspirin Responsiveness in Women at Risk for Cardiac Events
Lead Sponsor:
Creighton University
Conditions:
Heart Disease
Eligibility:
FEMALE
19+ years
Phase:
PHASE4
Brief Summary
The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be measured with ...
Eligibility Criteria
Inclusion
- Women at least 19 years old
- Taking 81 mg aspirin daily, non-enteric coated, for at least one month for the primary prevention of cardiovascular disease.
- Able and willing to provide informed consent
Exclusion
- Pregnancy or breastfeeding
- Known CHD
- Currently taking clopidogrel or ticlopidine
- Use of heparin, warfarin, or glycoprotein IIb/IIIa inhibitors within previous 96 hours
- Allergy or hypersensitivity to salicylates
- Use of other OTC or prescription analgesics or anti-inflammatory medication in the past two weeks
- Currently participating in another investigational drug or device study
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00818337
Start Date
November 1 2008
End Date
June 1 2009
Last Update
December 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Cardiac Center at Creighton University
Omaha, Nebraska, United States, 68131